Becton Dickinson Co (BDX) SEC Filing 10-Q Quarterly Report for the period ending Thursday, March 31, 2022

SEC Filings

BDX Quarterly Reports

Becton Dickinson Co

CIK: 10795 Ticker: BDX

Exhibit 99.1

1 Becton Drive
Franklin Lakes, NJ 07417


Investors: Francesca DeMartino, SVP, Head of Investor Relations - 201-847-5743
Media: Troy Kirkpatrick, VP, Public Relations - 858-617-2361


Revenue of $5.0 billion increased 2.1% as reported and 3.9% on currency-neutral basis
Revenue driven by base revenue growth of 8.2% as reported, 10.2% currency-neutral, partially offset by decline in worldwide COVID-only testing revenues to $214 million from $474 million in the prior year
GAAP diluted EPS of $1.50; adjusted diluted EPS of $3.18
Company raises mid-point of revenue and adjusted EPS guidance ranges; Adjusts for completed spin of Diabetes Care business

FRANKLIN LAKES, NJ (May 5, 2022)
- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its second quarter of fiscal year 2022, which ended March 31, 2022.

“We delivered another quarter of strong growth across our base business through continued focused execution and progress against our BD2025 strategy, despite a dynamic and challenging macro environment,” said Tom Polen, chairman, CEO and president of BD. “Our Grow-Simplify-Empower initiatives, innovation pipeline and capital deployment strategy are demonstrating momentum and we remain well-positioned to drive long-term growth and value for shareholders.”

Recent Business Highlights

BD continues to advance its innovation-driven growth strategy, tuck-in M&A and ESG initiatives.
Completed Embecta Corp. (embecta) spin of BD's former Diabetes Care business, which is now one of the largest pure-play diabetes management companies in the world. Spin demonstrates BD's ongoing commitment to its BD 2025 strategy, and creates two, independent companies with attractive long-term value for BD shareholders.
Completed the acquisition of Cytognos to expand from cancer discovery and diagnosis into post-treatment monitoring. Year-to-date, completed four strategic acquisitions aligned with innovation-driven growth strategy, committing about $500 million in capital to M&A.
Launched new family of BD reagents that enables researchers to break through resolution boundaries in flow cytometry. BD Horizon RealYellow™ 586 Reagents have potential to accelerate discovery and drug development in oncology, autoimmune disorders and infectious diseases.
Released new BD Rhapsody™ TCR/BCR Multiomic Assay which speeds discovery in autoimmune disorders, immuno-oncology and infectious diseases.

The following information was filed by Becton Dickinson Co (BDX) on Thursday, May 5, 2022 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Becton Dickinson Co's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Becton Dickinson Co.


Assess how Becton Dickinson Co's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Becton Dickinson Co's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools


Learn More
Bullish Bearish Neutral
Filter Sentiment:
Filter Category:
M & A
Filter Subcategory:
Cash Flow
Inside Becton Dickinson Co's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Cover Page
Condensed Consolidated Balance Sheets
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Comprehensive Income
Condensed Consolidated Statements Of Income
Basis Of Presentation
Benefit Plans
Benefit Plans (Detail)
Benefit Plans (Tables)
Business Restructuring Charges
Business Restructuring Charges (Detail)
Business Restructuring Charges (Tables)
Contingencies (Detail)
Contingencies (Policies)
Debt (Detail)
Derivative Instruments And Hedging Activities
Derivative Instruments And Hedging Activities (Tables)
Derivative Instruments And Hedging Activities - Additional Information (Detail)
Derivative Instruments And Hedging Activities - Schedule Of Notional Amounts Of Outstanding Derivative Positions (Detail)
Derivative Instruments And Hedging Activities Disclosure - Gains (Losses) On Net Investment Hedges (Details)
Earnings Per Share
Earnings Per Share (Tables)
Earnings Per Share - Weighted Average Common Shares Used In Computations Of Basic And Diluted Earnings Per Share (Detail)
Financial Instruments And Fair Value Measurements
Financial Instruments And Fair Value Measurements (Tables)
Financial Instruments And Fair Value Measurements - Additional Information (Detail)
Financial Instruments And Fair Value Measurements - Cash And Equivalents And Restricted Cash (Details)
Financial Instruments And Fair Value Measurements - Schedule Of Fair Value, Assets And Liabilities Measured On Recurring Basis (Details)
Financial Instruments And Fair Value Measurements - Transfer Of Financial Assets Accounted For As Sales (Details)
Intangible Assets
Intangible Assets (Tables)
Intangible Assets - Additional Information (Detail)
Intangible Assets - Components Of Intangible Assets (Detail)
Intangible Assets - Reconciliation Of Goodwill By Business Segment (Detail)
Revenues (Details)
Segment Data
Segment Data (Tables)
Segment Data - Additional Information (Detail)
Segment Data - Financial Information For Company's Segments (Detail)
Segment Data - Revenues By Geographic Areas (Detail)
Shareholders' Equity
Shareholders' Equity (Tables)
Shareholders' Equity - Accumulated Other Comprehensive Income (Loss) - Components And Changes Of Accumulated Other Comprehensive Income (Loss) (Detail)
Shareholders' Equity - Changes In Certain Components Of Shareholders' Equity (Details)

Material Contracts, Statements, Certifications & more

Becton Dickinson Co provided additional information to their SEC Filing as exhibits

Ticker: BDX
CIK: 10795
Form Type: 10-Q Quarterly Report
Accession Number: 0000010795-22-000040
Submitted to the SEC: Thu May 05 2022 11:57:01 AM EST
Accepted by the SEC: Thu May 05 2022
Period: Thursday, March 31, 2022
Industry: Surgical And Medical Instruments And Apparatus

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: